Biogen Idec Inc and Elan Corp Plc have notified regulators of two new cases of a potentially deadly brain disease in multiple sclerosis (MS) patients being treated with Tysabri.
-
2-Biogen, Elan Report Tysabri Brain Disease Cases -
Biogen says no new brain infections with TysabriBiogen Idec and its partner Elan Corp said on Tuesday no new cases of a potentially deadly brain infection have been seen among patients taking their Tysabri multiple sclerosis drug since it was re-introduced in July 2006. -
Tysabri May Cause Liver Damage, Health Officials SayThe controversial multiple sclerosis drug Tysabri can start causing liver damage within six days of the first dose, U.S. health officials said Wednesday. -
MS Drug Tysabri Approved for Crohn's Diseaseysabri, a controversial drug used to treat multiple sclerosis, may also be used for patients with a moderate to severe form of another autoimmune illness, Crohn's disease, the U.S. Food and Drug Administration announced Monday. -
No New Brain Infection Cases with Biogen's TysabriBiogen Idec Inc. said on Thursday that there have been no new confirmed cases of a potentially fatal brain infection associated with its multiple sclerosis drug Tysabri, generically known as natalizumab -
Stopping Tysabri May Worsen MSPeople suffering from multiple sclerosis who stopped taking the controversial drug Tysabri experienced a resurgence of brain lesions associated with their disease, researchers report.
